MedTrace Logo

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

NCT00757757 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-12-19

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer and bone metastases

Conditions

Interventions

DRUG

MCS110

Anti-M-CSF antibody

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00757757 on ClinicalTrials.gov